PMA device
xT CDx
Tempus AI, Inc. · Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP, Class III) · First FDA decision Apr 28, 2023, newest Sep 2, 2026Cancer detection and genomic testing
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
0
Naming "xT CDx"
MAUDE reports
0
Brand "xT CDx", since 2015
PubMed studies
0
Mentioning "xT CDx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing xT CDx
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- xT CDxPMA supplement
P210011-S002 · Decided Sep 2, 2026 · 572 days after receipt · Normal 180 Day Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- xT CDxPMA supplement
P210011-S004 · Decided May 28, 2026 · 332 days after receipt · Normal 180 Day Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- xT CDxPMA
P210011 · Decided Apr 28, 2023 · 766 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40210Palmetto GBAUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40278WPS Insurance CorporationUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40226CGS Administrators, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40222Noridian Healthcare Solutions, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40278WPS Insurance CorporationUpdated Sep 15, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40222Noridian Healthcare Solutions, LLCUpdated Aug 22, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40226CGS Administrators, LLCUpdated Aug 21, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40210Palmetto GBAUpdated Aug 18, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "xT CDx", any status and sponsor, newest update first.
No registered device study names "xT CDx".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "xT CDx", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PQP
14 reports: 11 malfunction, 2 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "xT CDx"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code PQP.
- FoundationOne CDxFoundation Medicine, Inc. · PMA 2026
- FoundationOne Liquid CDxFoundation Medicine, Inc. · PMA 2026
- Oncomine Dx Target TestLife Technologies Corporation · PMA 2025
- Guardant360 CDxGuardant Health, Inc. · PMA 2026
- Oncomine Dx Express TestLife Technologies Corporation · PMA 2026
- TruSight Oncology ComprehensiveIllumina, Inc. · PMA 2026
- FoundationOne®Liquid CDxFoundation Medicine, Inc. · PMA 2026
- FoundationOneCDx (F1CDx)Foundation Medicine, Inc. · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.